CERo Therapeutics Executives Flood Market with Zero‑Dollar Options as Shares Dive 25% in a Week—Is Management Betting on a Comeback?
Insider buying surge at CERo Therapeutics shows executive confidence amid a 44% monthly drop – read why investors should weigh this high‑volatility biotech bet.
3 minutes to read
